New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
16:37 EDTSHPG, ANIPANI Pharmaceuticals acquires U.S. rights for Vancocin from Shire
ANI Pharmaceuticals (ANIP) announced that it has acquired the U.S. rights for Vancocin 125 mg and 250 mg capsules from Shire (SHPG). In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11M in cash for the rights to Vancocin together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin capsules under its own label during the fourth quarter. The transaction is immediately accretive and sales of Vancocin capsules are expected to generate approximately $5.4M in revenues and $4M in non-GAAP EBITDA annually.
News For ANIP;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
16:00 EDTSHPGShire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.
February 3, 2016
08:07 EDTSHPGMedgenics names Brian Piper to succeed John Leaman as CFO
Subscribe for More Information
February 2, 2016
09:46 EDTSHPGIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
February 1, 2016
08:13 EDTANIPANI acquires exclusive rights to distribute three generics from H2 Pharma
ANI Pharmaceuticals announced that it has acquired the exclusive rights to distribute 1% and 2.5% hydrocortisone cream for rectal use and the exclusive rights to distribute the authorized generic of Lipofen from H2-Pharma, LLC for $10M. In addition, ANI also acquired an early stage development project for an undisclosed generic injectable drug product.
January 28, 2016
10:05 EDTSHPGHigh option volume stocks
Subscribe for More Information
January 25, 2016
07:02 EDTSHPGShire resubmits NDA for lifitegrast to FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use